Sign in
Taking people in United KingdomPhase 1/2

Tests repotrectinib in children and young adults with certain cancers

Tests repotrectinib in young people with solid tumors that have ALK, ROS1 or NTRK changes.

Key facts

Who runs it
Turning Point Therapeutics, Inc.
Where
Birmingham, Cardiff, Glasgow, Liverpool, and London, United KingdomSee the 6 sitesAlso in 10 other countries, 51 sites
Registry title
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Status
Recruiting
Phase
Phase 1/2
People taking part
75 people, planned
Started
12 Mar 2020
Expected to end
30 Sept 2027
Type of study
Interventional
Treatments tested
  • Oral repotrectinib (TPX-0005)
Record updated
25 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults with an advanced or spread cancer that carries a ROS1 or NTRK1-3 gene change. It tests the drug repotrectinib.

Age
Phase 1: under 12 years. Phase 2: 12 to 25 years.
Sex
All sexes can join.
Disease stage
Advanced or metastatic solid tumors, lymphoma or primary CNS tumors. The disease must be measurable by RECIST v1.1 or RANO criteria.
Earlier treatment
Earlier chemotherapy and immunotherapy are allowed. Side effects of earlier cancer treatment must have settled to grade 1 or less. In Phase 2, one NTRK cohort has had no earlier TRK TKI and another has had one.
Biomarker or test result
A ROS1 point mutation, fusion or amplification, or an NTRK1-3 fusion, found by testing in an accredited lab.

Main reasons for not taking part

  • Neuroblastoma with disease only in the bone marrow
  • Major surgery in the last 14 days
  • Active infection needing treatment, including HIV positivity
  • Gut disease that affects how drugs are absorbed
  • Heart rhythm problems, such as QTc over 480 msec

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Documented genetic ROS1 point mutation, fusion, or amplification or NTRK1-3 fusion as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required
  • Phase 1: Age <12 years; Phase 2: Age 12- 25 years
  • Prior cytotoxic chemotherapy is allowed
  • Prior immunotherapy is allowed
  • Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1
  • All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria at time of enrollment
  • Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment
  • Subjects must have a Lansky (< 16 years) or Karnofsky (≥ 16 years) score of at least 50
  • Life expectancy greater than or equal to 12 weeks, in the investigator's opinion
  • Adequate hematologic, renal and hepatic function; Phase 2 Inclusion Criteria:
  • Cohort Specific Inclusion Criteria:; Cohort 1: Subjects with NTRK fusion gene positive (NTRK+) advanced solid tumors (including primary CNS tumors), that are tropomyosin receptor kinase (TRK) TKI naïve; Cohort 2: subjects with NTRK+ advanced solid tumors (including primary CNS tumors), that are TRK TKI pre-treated; Cohort 3: subjects with advanced solid tumors with ROS1 gene fusions or other ROS1 aberrations (including amplifications and point mutations) with measurable disease
  • Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by BICR prior to enrollment

Who cannot take part

  • Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery
  • Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers
  • Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only
  • Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity)
  • Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption
  • Any potential allergies to repotrectinib and/or its excipients
  • Any of the following cardiac criteria:; Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) > 480 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value; Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec); Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
  • Peripheral neuropathy of CTCAE ≥grade 2

Where in United Kingdom

Also in 10 other countries, 51 sites

  • BirminghamHospital not named in the registryNo longer taking part
  • University Hospital of WalesCardiff, United KingdomContact: Madeleine Adams, Site 4401Taking people
  • Royal Hosp. for ChildrenGlasgow, United KingdomContact: Milind Ronghe, Site 4406Taking people
  • Alder Hey Children's NHS Foundation TrustLiverpool, United KingdomContact: Lisa Howell, Site 4404Taking people
  • Great Ormond Street Hospital For Children NHS Foundation TrustLondon, United KingdomContact: Elwira Szychot, Site 4402Taking people
  • The Royal Marsden NHS Foundation TrustLondon, United KingdomContact: Linley Marchall, Site 4405Taking people

About the trial

What the trial wants to find out

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D).

Read full original descriptionShow less

Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.

The group in the trial

  • Repotrectinib (TPX-0005)Treatment being tested

    Phase 1 Oral repotrectinib (TPX-0005): Safety and tolerability at different dose levels Phase 2 Oral repotrectinib (TPX-0005): 3 cohorts Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ROS1 gene fusions or other ROS1 aberrations

    Treatment: Oral repotrectinib (TPX-0005)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
Plain-language title
Tests repotrectinib in children and young adults with certain cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
25 September 2026